Snapshot
Abbott Laboratories reported $11.14B of revenue in Q2 2025, up 7.4% year over year, with diluted EPS of $1.01 and an operating margin of 18.4%.
- Revenue
- $11.14B
- YoY growth
- +7.4%
- Diluted EPS
- $1.01
- Operating margin
- 18.4%
$11.14B
Revenue
+7.4%
YoY growth
$1.01
Diluted EPS
18.4%
Operating margin
01 Key takeaways
What management said
- •These non-GAAP financial measures are reconciled with the comparable GAAP financial measures in our earnings news release and regulatory filings from today, which are available on our website at abbott.com.
- •Unless otherwise noted, our commentary on sales growth refers to organic sales growth, which is defined in the press release issued earlier today.
- •Our sales growth excluded COVID testing sales was 7.5% in the second quarter and 8% in the first half of the year.
- •Our second quarter adjusted earnings per share of $1.26 exceeded the consensus estimate and reflects 11% growth versus the prior year and 16% growth on a sequential basis compared to the first quarter.
- •Growth in the quarter was driven by 6.5% growth in adult nutrition, where Abbott is the global market leader.
- •Together, these represent a projected headwind of around $700 million or 750 basis points on the full year 2025 sales growth in diagnostics.
- •Excluding China, Core Lab Diagnostics grew 8%, reflecting strong underlying demand in the markets around the world.
- •These markets represent the most attractive areas of growth for branded generic medicines.
- •The growth in these markets is supported by favorable long-term healthcare, economic, and demographic trends, including higher birth rates, an expanding middle-class aging population, and growing demand for access to high-quality healthcare solutions.
- •We serve this growing demand by offering a broad portfolio of branded generic medicines tailored to local conditions with a focus on key therapeutic areas.
- •I'll wrap up with medical devices, where sales grew 12%, driven by double-digit growth in diabetes care, heart failure, structural heart, electrophysiology, and cardiac rhythm management.
- •In diabetes care, sales of continuous glucose monitors were $1.9 billion in the quarter and grew 19.5%.
SourcesCompany financials · earnings call
Last updated